Schrödinger, Inc.

SDGR

US80810D1037

Software

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
23.97 ^USD	+2.70%		-1.32%	-33.04%

Mar. 01	Citigroup Cuts Schrodinger Price Target to $39 From $47, Maintains Buy Rating	MT
Mar. 01	Goldman Sachs Cuts Schrodinger's Price Target to $26 From $29, Keeps Neutral Rating	MT

Schrödinger, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 28, 2024 at 04:07 pm EST

Schrödinger, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 57.54 million compared to USD 45.38 million a year ago. Revenue was USD 216.67 million compared to USD 180.96 million a year ago.

Net income was USD 40.72 million compared to net loss of USD 149.19 million a year ago. Basic earnings per share from continuing operations was USD 0.57 compared to basic loss per share from continuing operations of USD 2.1 a year ago. Diluted earnings per share from continuing operations was USD 0.54 compared to diluted loss per share from continuing operations of USD 2.1 a year ago.

Latest news about Schrödinger, Inc.

Citigroup Cuts Schrodinger Price Target to $39 From $47, Maintains Buy Rating	Mar. 01	MT
Goldman Sachs Cuts Schrodinger's Price Target to $26 From $29, Keeps Neutral Rating	Mar. 01	MT
Piper Sandler Cuts Price Target on Schrodinger to $50 From $60, Maintains Overweight Rating	Feb. 29	MT
Schrodinger's Q4 Adjusted Net Loss Narrows, Revenue Increases; Shares Down Pre-Bell	Feb. 29	MT
Transcript : Schrödinger, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (SDGR) SCHRODINGER Posts Q4 Revenue $74.1M, vs. Street Est of $79.1M	Feb. 28	MT
Schrödinger, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
TD Cowen Starts Schrodinger With Outperform Rating, $42 Price Target	Jan. 26	MT
Sector Update: Health Care Stocks Ease Thursday Afternoon	Dec. 14	MT
Schrodinger Shares Rise as SGR-1505 Seen Well-tolerated in Early Trial; Three New Gene Mutation Programs Added	Dec. 14	MT
Transcript : Schrödinger, Inc. - Special Call	Dec. 14
Schrodinger Says New Data Show 'Multiple Favorable Attributes' of Potential Leukemia Treatments	Dec. 11	MT
KeyBanc Initiates Schrodinger at Overweight With $38 Price Target, Cites 'Healthy Recurring Revenue Growth' in Software & Services, 'Attractive Valuation'	Dec. 05	MT
Morgan Stanley Trims Price Target on Schrodinger to $51 From $52, Maintains Equal-Weight Rating	Nov. 13	MT
Transcript : Schrödinger, Inc., Q3 2023 Earnings Call, Nov 01, 2023	Nov. 01
Schrodinger Q3 Non-GAAP Loss Widens, Revenue Increases	Nov. 01	MT
Earnings Flash (SDGR) SCHRODINGER Posts Q3 Revenue $42.6M, vs. Street Est of $37.9M	Nov. 01	MT
Schrödinger, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
BofA Securities Lowers Price Target on Schrodinger to $39 From $48, Maintains Neutral Rating	23-10-20	MT
Copernic Catalysts, Inc. Announces Research Collaboration with Schrödinger, Inc. to Accelerate Sustainable Catalyst Discovery	23-10-03	CI
Schrödinger, New York City College of Technology, and LaGuardia Community College Receives $1 Million Grant from the National Science Foundation to Increase Access to Computational Molecular Modeling Education	23-09-28	CI
Transcript : Schrödinger, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 02:15 PM	23-09-12
Insider Sell: Schrodinger	23-08-10	MT
Top Premarket Decliners	23-08-03	MT
Transcript : Schrödinger, Inc., Q2 2023 Earnings Call, Aug 02, 2023	23-08-02

Chart Schrödinger, Inc.

Duration

Period

More charts

Company Profile

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.

Sector

Software

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Schrödinger, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.97 USD

Average target price

37.7 USD

Spread / Average Target

+57.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Software

	1st Jan change	Capi.
SCHRÖDINGER, INC.	-33.04%	1.74B
MICROSOFT CORPORATION	+8.05%	3,020B
SYNOPSYS INC.	+5.58%	82.93B
CADENCE DESIGN SYSTEMS, INC.	+3.69%	76.85B
DASSAULT SYSTÈMES SE	-14.62%	53.04B
PALANTIR TECHNOLOGIES INC.	+31.16%	50.15B
ATLASSIAN CORPORATION	-24.56%	46.71B
THE TRADE DESK, INC.	+17.75%	41.41B
SEA LIMITED	+55.21%	36.1B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-10.24%	24.64B

Other Software